HLA-B

Protein-coding gene in the species Homo sapiens
HLA-B
Available structures
PDBHuman UniProt search: PDBe RCSB
List of PDB id codes

3VCL, 4U1H, 4U1K, 5EO1, 5EO0,%%s1AGB, 1AGC, 1AGD, 1AGE, 1AGF, 1M05, 1MI5, 3FFC, 3SJV, 3SKM, 3SKO, 3SPV, 3X13, 3X14, 4QRP, 4QRQ, 4QRS, 4QRT, 4QRU,%%s4O2C, 4O2E, 4O2F,%%s3LN4, 3LN5,%%s4U1J, 4U1M, 4U1N,%%s4U1I, 4U1L, 4U1S,%%s1HSA, 1JGD, 1JGE, 1K5N, 1OF2, 1OGT, 1UXS, 1UXW, 1W0V, 1W0W, 2A83, 2BSR, 2BSS, 2BST, 3B3I, 3B6S, 3BP4, 3BP7, 3CZF, 3D18, 3DTX, 3HCV, 3LV3, 4G8G, 4G8I, 4G9D, 4G9F, 5DEF, 5DEG,%%s1A1N, 1A9B, 1A9E, 1CG9, 1XH3, 1ZHK, 1ZHL, 1ZSD, 2AK4, 2AXF, 2AXG, 2H6P, 2NW3, 2NX5, 3BW9, 3BWA, 3KWW, 3KXF, 3LKN, 3LKO, 3LKP, 3LKQ, 3LKR, 3LKS, 3MV7, 3MV8, 3MV9, 3VFS, 3VFT, 3VFU, 3VFV, 3VFW, 4LNR, 4PR5, 4PRN, 4QRR,%%s1A1M, 1A1O,%%s2BVO, 2BVP, 2BVQ, 2HJL, 2RFX, 2YPK, 2YPL, 3UPR, 3VH8, 3VRI, 3VRJ, 3WUW, 3X11, 3X12, 5B39, 5B38,%%s4JQV, 4XXC,%%s1XR8, 1XR9, 3C9N,%%s4LCY,%%s1M6O, 1N2R, 1SYV, 3DX6, 3DX7, 3DX8, 3DXA, 3KPL, 3KPM, 3KPN, 3KPO, 3KPP, 3KPQ, 3KPR, 3KPS, 3L3D, 3L3G, 3L3I, 3L3J, 4JQX,%%s1E27, 1E28, 4MJI,%%s3W39

Identifiers
AliasesHLA-B, AS, SPDA1, Bw-47, Bw-50, major histocompatibility complex, class I, B, B-4901, B-5001, HEL-S-83, HLA-B*45ZJ, HLA-B-3506, HLA-B-3905, HLA-B-5502, HLA-B-5602, HLA-B15, HLA-B39, HLA-B49, HLA-B50, HLA-B55, HLA-B59, HLA-B61, HLA-Cw, HLA-DRB1
External IDsHomoloGene: 134029 GeneCards: HLA-B
Gene location (Human)
Chromosome 6 (human)
Chr.Chromosome 6 (human)[1]
Chromosome 6 (human)
Genomic location for HLA-B
Genomic location for HLA-B
Band6p21.33Start31,353,872 bp[1]
End31,367,067 bp[1]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • blood

  • spleen

  • upper lobe of left lung

  • appendix

  • bone marrow cells

  • right lung

  • monocyte

  • lymph node

  • gallbladder

  • stromal cell of endometrium
    n/a
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • signaling receptor binding
  • peptide antigen binding
Cellular component
  • integral component of membrane
  • phagocytic vesicle membrane
  • Golgi apparatus
  • early endosome membrane
  • membrane
  • Golgi membrane
  • plasma membrane
  • integral component of plasma membrane
  • cell surface
  • endoplasmic reticulum
  • MHC class I protein complex
  • ER to Golgi transport vesicle membrane
  • integral component of lumenal side of endoplasmic reticulum membrane
  • extracellular exosome
  • secretory granule membrane
  • recycling endosome membrane
Biological process
  • antigen processing and presentation
  • antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent
  • regulation of interleukin-12 production
  • interferon-gamma-mediated signaling pathway
  • immune system process
  • antigen processing and presentation of peptide antigen via MHC class I
  • regulation of dendritic cell differentiation
  • antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent
  • protection from natural killer cell mediated cytotoxicity
  • type I interferon signaling pathway
  • immune response
  • regulation of immune response
  • regulation of T cell anergy
  • viral process
  • regulation of interleukin-6 production
  • neutrophil degranulation
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

3106

n/a

Ensembl
ENSG00000228964
ENSG00000234745
ENSG00000206450
ENSG00000224608
ENSG00000223532

ENSG00000232126

n/a

UniProt

P01889

n/a

RefSeq (mRNA)

NM_005514

n/a

RefSeq (protein)

NP_005505

n/a

Location (UCSC)Chr 6: 31.35 – 31.37 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

HLA-B (major histocompatibility complex, class I, B) is a human gene that provides instructions for making a protein that plays a critical role in the immune system. HLA-B is part of a family of genes called the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria.

HLA is the human version of the major histocompatibility complex (MHC), a gene family that occurs in many species. Genes in this complex are separated into three basic groups: class I, class II, and class III. In humans, the HLA-B gene and two related genes, HLA-A and HLA-C, are the major genes in MHC class I.

MHC class I genes provide instructions for making proteins that are present on the surface of almost all cells. On the cell surface, these proteins are bound to protein fragments (peptides) that have been exported from within the cell. MHC class I proteins display these peptides to the immune system. If the immune system recognizes the peptides as foreign (such as viral or bacterial peptides), it responds by destroying the infected cell.

The HLA-B gene has many different normal variations, allowing each person's immune system to react to a wide range of foreign invaders. Hundreds of versions (alleles) of HLA-B are known, each of which is given a particular number (such as HLA-B27). Closely related alleles are categorized together; for example, at least 28 very similar alleles are subtypes of HLA-B27. These subtypes are designated as HLA-B*2701 to HLA-B*2728.

The HLA-B gene is located on the short (p) arm of chromosome 6 at cytoband 21.3, from base pair 31,353,871 to 31,357,211 [3]

Related conditions

Serotypes of HLA-B gene products
antigen - Broad
antigen
Split antigens
B7 B5 B51 B52
B8 B12 B44 B45
B13 B14 B64 B65
B18 B15 B62 B63 B70
B27 B72 B75 B77
B35 B16 B38 B39
B37 B17 B57 B58
B41 B21 B49 B50
B42 B22 B54 B55 B56
B46 B40 B60 B61
B47
B48
B53
B59
B67
B73
B78
B81
B*82
B*83
"HLA-" prefix trimmed from serotype names.

Ankylosing spondylitis: A version of the HLA-B gene called HLA-B27 increases the risk of developing ankylosing spondylitis. It is uncertain how HLA-B27 causes this increased risk. Researchers speculate that HLA-B27 may abnormally display to the immune system peptides that trigger arthritis. Other research suggests that joint inflammation characteristic of this disorder may result from improper folding of the HLA-B27 protein or the presence of abnormal forms of the protein on the cell surface. Although most patients with ankylosing spondylitis have the HLA-B27 variation, many people with this particular variation never develop the disorder. Other genetic and environmental factors are likely to affect the chances of developing ankylosing spondylitis and influence its progression.

In addition to Ankylosing spondylitis, HLA-B27 is associated with other spondyloarthropathies, a group of related inflammatory joint diseases. Some of these diseases are associated with a common skin condition called psoriasis or chronic inflammatory bowel disorders (Crohn's disease and ulcerative colitis). One of the spondyloarthropathies, reactive arthritis, is typically triggered by bacterial infections of the gastrointestinal or genital tract. Following an infection, affected individuals may develop arthritis, back pain, and eye inflammation. Like ankylosing spondylitis, many factors probably contribute to the development of reactive arthritis and other spondyloarthropathies.

A large number of studies have shown an association between HLA-B51 And Behçet's disease.

Other disorders: Several variations of the HLA-B gene are associated with adverse reactions to certain drugs. For example, two specific versions of this gene are related to increased drug sensitivity among the Han Chinese population. Individuals who have HLA-B*1502 are more likely to experience a severe skin disorder called Stevens–Johnson syndrome in response to carbamazepine (a drug used to treat seizures). Another version, HLA-B*5801, is associated with an increased risk of severe skin reactions in people treated with allopurinol (a drug used to treat gout, which is a form of arthritis caused by uric acid in the joints).

Among people with human immunodeficiency virus (HIV) infection, a version of HLA-B designated HLA-B*5701 is associated with an extreme sensitivity to abacavir. This drug is a treatment for HIV-1 that slows the spread of the virus in the body. People with abacavir hypersensitivity often develop a fever, chills, rash, upset stomach, and other symptoms when treated with this drug.

Several other variations of the HLA-B gene appear to play a role in the progression of HIV infection to acquired immunodeficiency syndrome (AIDS). AIDS is a disease that damages the immune system, preventing it from effectively defending the body against infections. The signs and symptoms of AIDS may not appear until 10 years or more after infection with HIV. Studies suggest that people with HIV infection who have HLA-B27 or HLA-B57 tend to progress more slowly than usual to AIDS. On the other hand, researchers believe that HIV-positive individuals who have HLA-B35 tend to develop the signs and symptoms of AIDS more quickly than usual. Other factors also influence the progression of HIV to AIDS.

Another version of the HLA-B gene, HLA-B53, has been shown to help protect against severe malaria.[4] HLA-B53 is most common in West African populations, where malaria is a frequent cause of death in children. Researchers suggest that this version of the HLA-B gene may help the immune system respond more effectively to the parasite that causes malaria.

HLA-B and graft compatibility

HLA-B is one of three major HLAs that should be matched between donors and recipients. They are HLA-A, HLA-B, (both Class I MHCs) and HLA-DR (a Class II MHC).[5] If the two tissues have the same genes coding for these three HLAs, the likelihood and severity of rejection is minimized.[6]

See also

References

  1. ^ a b c ENSG00000234745, ENSG00000206450, ENSG00000224608, ENSG00000223532, ENSG00000232126 GRCh38: Ensembl release 89: ENSG00000228964, ENSG00000234745, ENSG00000206450, ENSG00000224608, ENSG00000223532, ENSG00000232126 – Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ "HLA-B gene".
  4. ^ Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM (August 1991). "Common west African HLA antigens are associated with protection from severe malaria". Nature. 352 (6336): 595–600. Bibcode:1991Natur.352..595H. doi:10.1038/352595a0. PMID 1865923. S2CID 2667496.
  5. ^ Fix M (1998). "HLA Matching, Antibodies, and You". Kidney Transplantation: Past, Present, and Future. University of Michigan Medical Center/Stanford University. Archived from the original on 9 March 2014. Retrieved 14 Dec 2013.
  6. ^ Solomon S, Pitossi F, Rao MS (February 2015). "Banking on iPSC--is it doable and is it worthwhile". Stem Cell Reviews. 11 (1): 1–10. doi:10.1007/s12015-014-9574-4. PMC 4333229. PMID 25516409.

Further reading

  • Brown MA, Crane AM, Wordsworth BP (July 2002). "Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis". Current Opinion in Rheumatology. 14 (4): 354–60. doi:10.1097/00002281-200207000-00004. PMID 12118167. S2CID 34447784.
  • Carrington M, O'Brien SJ (2003). "The influence of HLA genotype on AIDS". Annual Review of Medicine. 54: 535–51. doi:10.1146/annurev.med.54.101601.152346. PMID 12525683.
  • Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT (April 2004). "Medical genetics: a marker for Stevens-Johnson syndrome". Nature. 428 (6982): 486. Bibcode:2004Natur.428..486C. doi:10.1038/428486a. PMID 15057820. S2CID 4423593.
  • Colbert RA (February 2004). "The immunobiology of HLA-B27: variations on a theme". Current Molecular Medicine. 4 (1): 21–30. doi:10.2174/1566524043479293. PMID 15011956.
  • Colmegna I, Cuchacovich R, Espinoza LR (April 2004). "HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations". Clinical Microbiology Reviews. 17 (2): 348–69. doi:10.1128/CMR.17.2.348-369.2004. PMC 387405. PMID 15084505. Full text
  • Cooke GS, Hill AV (December 2001). "Genetics of susceptibility to human infectious disease". Nature Reviews. Genetics. 2 (12): 967–77. doi:10.1038/35103577. PMID 11733749. S2CID 19847857.
  • Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, O'Brien SJ, Carrington M (May 2001). "Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS". The New England Journal of Medicine. 344 (22): 1668–75. doi:10.1056/NEJM200105313442203. PMID 11386265.
  • Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD (March 2002). "Genetic variations in HLA-B region and hypersensitivity reactions to abacavir". Lancet. 359 (9312): 1121–2. doi:10.1016/S0140-6736(02)08158-8. PMID 11943262. S2CID 9434238.
  • Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (March 2005). "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol". Proceedings of the National Academy of Sciences of the United States of America. 102 (11): 4134–9. Bibcode:2005PNAS..102.4134H. doi:10.1073/pnas.0409500102. PMC 554812. PMID 15743917. Full text
  • Khan MA, Ball EJ (September 2002). "Genetic aspects of ankylosing spondylitis". Best Practice & Research. Clinical Rheumatology. 16 (4): 675–90. doi:10.1053/berh.2002.0243. PMID 12406434.
  • Khan MA (June 2002). "Update on spondyloarthropathies". Annals of Internal Medicine. 136 (12): 896–907. CiteSeerX 10.1.1.694.2473. doi:10.7326/0003-4819-136-12-200206180-00011. PMID 12069564. S2CID 45831036. Full text (PDF)
  • Letvin NL, Walker BD (July 2003). "Immunopathogenesis and immunotherapy in AIDS virus infections". Nature Medicine. 9 (7): 861–6. doi:10.1038/nm0703-861. PMID 12835706. S2CID 10395676.
  • Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M (March 2000). "HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors". Proceedings of the National Academy of Sciences of the United States of America. 97 (6): 2709–14. Bibcode:2000PNAS...97.2709M. doi:10.1073/pnas.050567397. PMC 15994. PMID 10694578. Full text Archived 2007-11-26 at the Wayback Machine
  • Sheehan NJ (January 2004). "The ramifications of HLA-B27". Journal of the Royal Society of Medicine. 97 (1): 10–4. doi:10.1177/014107680409700102. PMC 1079257. PMID 14702356.
  • Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (September 2009). "Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population". Pharmacogenetics and Genomics. 19 (9): 704–9. doi:10.1097/FPC.0b013e328330a3b8. PMID 19696695. S2CID 24941838.
  • Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K, Kulkantrakorn K, Choonhakarn C, Phonhiamhan S, Piyatrakul N, Aungaree T, Pongpakdee S, Yodnopaglaw P (May 2010). "Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population". Epilepsia. 51 (5): 926–30. doi:10.1111/j.1528-1167.2010.02533.x. PMID 20345939. S2CID 27093314. Full text(PDF)
  • v
  • t
  • e
  • 1a1n: MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1
    1a1n: MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1
  • 1a9b: DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
    1a9b: DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
  • 1a9e: DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
    1a9e: DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
  • 1agb: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION)
    1agb: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION)
  • 1agc: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION)
    1agc: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION)
  • 1agd: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE)
    1agd: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE)
  • 1age: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION)
    1age: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION)
  • 1agf: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION)
    1agf: ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION)
  • 1cg9: COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
    1cg9: COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
  • 1e27: NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1(LPPVVAKEI)
    1e27: NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1(LPPVVAKEI)
  • 1e28: NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2(TAFTIPSI)
    1e28: NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2(TAFTIPSI)
  • 1efx: STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
    1efx: STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
  • 1hsa: THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
    1hsa: THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
  • 1jgd: HLA-B*2709 bound to deca-peptide s10R
    1jgd: HLA-B*2709 bound to deca-peptide s10R
  • 1jge: HLA-B*2705 bound to nona-peptide m9
    1jge: HLA-B*2705 bound to nona-peptide m9
  • 1k5n: HLA-B*2709 BOUND TO NONA-PEPTIDE M9
    1k5n: HLA-B*2709 BOUND TO NONA-PEPTIDE M9
  • 1m05: HLA B8 in complex with an Epstein Barr Virus determinant
    1m05: HLA B8 in complex with an Epstein Barr Virus determinant
  • 1mi5: The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex
    1mi5: The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex
  • 1of2: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
    1of2: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
  • 1ogt: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
    1ogt: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
  • 1uxs: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
    1uxs: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
  • 1uxw: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
    1uxw: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
  • 1w0v: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
    1w0v: CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
  • 1w0w: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
    1w0w: CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
  • 1xh3: Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501
    1xh3: Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501
  • 1xr8: Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
    1xr8: Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
  • 1xr9: Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
    1xr9: Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus EBNA-3
  • 1zhk: Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen LPEPLPQGQLTAY
    1zhk: Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen LPEPLPQGQLTAY
  • 1zhl: Crystal structure of HLA-B*3508 presenting 13-mer EBV antigen LPEPLPQGQLTAY
    1zhl: Crystal structure of HLA-B*3508 presenting 13-mer EBV antigen LPEPLPQGQLTAY
  • 1zsd: Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen EPLPQGQLTAY
    1zsd: Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen EPLPQGQLTAY
  • 2a83: Crystal structure of hla-b*2705 complexed with the glucagon receptor (gr) peptide (residues 412-420)
    2a83: Crystal structure of hla-b*2705 complexed with the glucagon receptor (gr) peptide (residues 412-420)
  • 2ak4: Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
    2ak4: Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide
  • 2axf: The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
    2axf: The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
  • 2axg: The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
    2axg: The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation
  • 2bsr: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
    2bsr: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
  • 2bss: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
    2bss: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
  • 2bst: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
    2bst: CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
  • 2cik: INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450.
    2cik: INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450.
  • 2fyy: The role of T cell receptor alpha genes in directing human MHC restriction
    2fyy: The role of T cell receptor alpha genes in directing human MHC restriction
  • 2fz3: The role of T cell receptor alpha genes in directing human MHC restriction
    2fz3: The role of T cell receptor alpha genes in directing human MHC restriction
  • 2h6p: Crystal structure of HLA-B*3501 presenting the human cytochrome P450 derived peptide, KPIVVLHGY
    2h6p: Crystal structure of HLA-B*3501 presenting the human cytochrome P450 derived peptide, KPIVVLHGY
  • 2nw3: Crystal structure of HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A
    2nw3: Crystal structure of HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A
  • 2nx5: Crystal structure of ELS4 TCR bound to HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A
    2nx5: Crystal structure of ELS4 TCR bound to HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A

This article incorporates public domain text from The U.S. National Library of Medicine

External links

  • Nomenclature for factors of the HLA system
  • Overview of all the structural information available in the PDB for UniProt: P01889 (HLA class I histocompatibility antigen, B alpha chain) at the PDBe-KB.